PURPOSE: Adverse drug events (ADEs) lead to adverse clinical outcomes such as hospitalization. There is little information about the characteristics of ADEs in patients with advanced chronic conditions and have a prognosis of limited life expectancy. This study aimed to evaluate (i) the prevalence of ADEs at the time of admission to hospital, (ii) the causality, severity, and preventability of the ADEs, and (iii) the clinical and pharmacological characteristics associated with the ADEs. METHODS: This is a prospective cross-sectional study (county of Osona, Catalonia, Spain). We included patients who required palliative care as identified by the NECPAL CCOMS-ICO tool who were hospitalized in an acute geriatric unit (AGU). A system of alerts (trigger tool) was used together with a multidisciplinary review for the detection of the ADEs. RESULTS: Over the course of 10 months, 235 patients were recruited. Seventy-six ADEs affecting 24.68 % of the sample were identified, and of these, 23 (30.26 % of the ADEs; 8.51 % of the sample) were directly related to hospitalization. The multivariate logistic regression analysis identified the following risk factors: presence of extreme polypharmacy (≥10 medications) (OR = 3.02; 95 % CI = 1.48-6.19), anticholinergic burden according to the Anticholinergic Drug Scale (ADS) (OR = 2.32; 95 % CI = 1.13-4.78), and treatment complexity according to the Medication Regimen Complexity Index (MRCI) scale (OR = 2.90; 95 % CI = 1.44-5.83). The vast majority (94.45 %) of the ADEs were considered to be preventable. There were no differences in the survival of the patients. CONCLUSIONS: ADEs are common, largely preventable, and implicated in the hospitalization of patients who require palliative care.
PURPOSE: Adverse drug events (ADEs) lead to adverse clinical outcomes such as hospitalization. There is little information about the characteristics of ADEs in patients with advanced chronic conditions and have a prognosis of limited life expectancy. This study aimed to evaluate (i) the prevalence of ADEs at the time of admission to hospital, (ii) the causality, severity, and preventability of the ADEs, and (iii) the clinical and pharmacological characteristics associated with the ADEs. METHODS: This is a prospective cross-sectional study (county of Osona, Catalonia, Spain). We included patients who required palliative care as identified by the NECPAL CCOMS-ICO tool who were hospitalized in an acute geriatric unit (AGU). A system of alerts (trigger tool) was used together with a multidisciplinary review for the detection of the ADEs. RESULTS: Over the course of 10 months, 235 patients were recruited. Seventy-six ADEs affecting 24.68 % of the sample were identified, and of these, 23 (30.26 % of the ADEs; 8.51 % of the sample) were directly related to hospitalization. The multivariate logistic regression analysis identified the following risk factors: presence of extreme polypharmacy (≥10 medications) (OR = 3.02; 95 % CI = 1.48-6.19), anticholinergic burden according to the Anticholinergic Drug Scale (ADS) (OR = 2.32; 95 % CI = 1.13-4.78), and treatment complexity according to the Medication Regimen Complexity Index (MRCI) scale (OR = 2.90; 95 % CI = 1.44-5.83). The vast majority (94.45 %) of the ADEs were considered to be preventable. There were no differences in the survival of the patients. CONCLUSIONS: ADEs are common, largely preventable, and implicated in the hospitalization of patients who require palliative care.
Authors: Lise Carnevali; Bruno Krug; Fabienne Amant; Dominique Van Pee; Véronique Gérard; Xavier de Béthune; Anne Spinewine Journal: Ann Pharmacother Date: 2013-11 Impact factor: 3.154
Authors: Rikje Ruiter; Loes E Visser; Eline M Rodenburg; Gianluca Trifiró; Gijsbertus Ziere; Bruno H Stricker Journal: Drugs Aging Date: 2012-03-01 Impact factor: 3.923
Authors: Danijela Gnjidic; Sarah N Hilmer; Fiona M Blyth; Vasi Naganathan; Louise Waite; Markus J Seibel; Andrew J McLachlan; Robert G Cumming; David J Handelsman; David G Le Couteur Journal: J Clin Epidemiol Date: 2012-06-27 Impact factor: 6.437
Authors: Marilisa Franceschi; Carlo Scarcelli; Valeria Niro; Davide Seripa; Anna Maria Pazienza; Giovanni Pepe; Anna Maria Colusso; Luigi Pacilli; Alberto Pilotto Journal: Drug Saf Date: 2008 Impact factor: 5.606
Authors: Joanna E Klopotowska; Peter C Wierenga; Clementine C M Stuijt; Lambertus Arisz; Marcel G W Dijkgraaf; Paul F M Kuks; Henk Asscheman; Sophia E de Rooij; Loraine Lie-A-Huen; Susanne M Smorenburg Journal: PLoS One Date: 2013-08-05 Impact factor: 3.240
Authors: Khedidja Hedna; Katja M Hakkarainen; Hanna Gyllensten; Anna K Jönsson; Max Petzold; Staffan Hägg Journal: Eur J Clin Pharmacol Date: 2015-09-26 Impact factor: 2.953
Authors: Maria das Dores Graciano Silva; Maria Auxiliadora Parreiras Martins; Luciana de Gouvêa Viana; Luiz Guilherme Passaglia; Renata Rezende de Menezes; João Antonio de Queiroz Oliveira; Jose Luiz Padilha da Silva; Antonio Luiz Pinho Ribeiro Journal: Br J Clin Pharmacol Date: 2018-07-08 Impact factor: 4.335
Authors: Núria Molist-Brunet; Daniel Sevilla-Sánchez; Emma Puigoriol-Juvanteny; Lorena Bajo-Peñas; Immaculada Cantizano-Baldo; Laia Cabanas-Collell; Joan Espaulella-Panicot Journal: Int J Environ Res Public Health Date: 2022-03-14 Impact factor: 3.390